866-997-4948(US-Canada Toll Free)

Dermatomycoses - Pipeline Review, H2 2016

Published By :

Global Markets Direct

Published Date : Nov 2016

Category :

Pharmaceutical

No. of Pages : 61 Pages

Dermatomycoses - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Dermatomycoses - Pipeline Review, H2 2016, provides an overview of the Dermatomycoses (Infectious Disease) pipeline landscape.

Dermatophytes cause fungal infections of keratinized tissues, e.g. skin, hair and nails. The organisms belong to 3 genera, Trichophyton, Epidermophyton and Microsporum. Dermatophytes may be grouped into 3 categories based on host preference and natural habitat. Anthropophilic species predominantly infect humans, geophilic species are soil based and may infect both humans and animals, zoophilic species generally infect non-human mammals.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Dermatomycoses - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Dermatomycoses (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Dermatomycoses (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Dermatomycoses and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 4, 1, 5 and 1 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.Dermatomycoses.

Dermatomycoses (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Dermatomycoses (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Dermatomycoses (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Dermatomycoses (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Dermatomycoses (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Dermatomycoses (Infectious Disease)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Dermatomycoses (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Dermatomycoses (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Dermatomycoses Overview 7
Therapeutics Development 8
Pipeline Products for Dermatomycoses - Overview 8
Pipeline Products for Dermatomycoses - Comparative Analysis 9
Dermatomycoses - Therapeutics under Development by Companies 10
Dermatomycoses - Therapeutics under Investigation by Universities/Institutes 11
Dermatomycoses - Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Early Stage Products 14
Unknown Stage Products 15
Dermatomycoses - Products under Development by Companies 16
Dermatomycoses - Products under Investigation by Universities/Institutes 17
Dermatomycoses - Companies Involved in Therapeutics Development 18
Anacor Pharmaceuticals Inc 18
Biolab Farmaceutica Ltda 19
Blueberry Therapeutics Ltd 20
Daewoong Pharmaceutical Co Ltd 21
Dermala Inc 22
Helix BioMedix Inc 23
Novan Inc 24
Sol-Gel Technologies Ltd 25
TGV-Laboratories 26
Viamet Pharmaceuticals Inc 27
Vyome Biosciences Pvt Ltd 28
Dermatomycoses - Therapeutics Assessment 29
Assessment by Monotherapy Products 29
Assessment by Target 30
Assessment by Mechanism of Action 32
Assessment by Route of Administration 34
Assessment by Molecule Type 36
Drug Profiles 38
AN-2718 - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
BB-2603 - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
clotrimazole - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
dapaconazole - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
Drug for Athlete's Foot - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
DWP-06081 - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
E-06 - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
HB-1275 - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
luliconazole - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
Myc-102 - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
nitric oxide - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
SB-208 - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
Small Molecule for Fungal Infections - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
VT-1161 - Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
Dermatomycoses - Dormant Projects 56
Dermatomycoses - Product Development Milestones 57
Featured News & Press Releases 57
Jul 21, 2016: Novan Announces First Patient Dosed in Phase 2 Anti-Fungal Program 57
Jul 15, 2015: Viamet to Present at American Podiatric Medical Association 2015 Annual Scientific Meeting 57
Jul 09, 2014: Viamet Reports Additional Positive Interim Results of Phase 2 Studies of VT-1161 with Moderate to Severe Interdigital Tinea Pedis 58
Mar 12, 2014: Viamet Reports Positive Interim Results of Phase 2 Interdigital Tinea Pedis Study of VT-1161 58
Appendix 60
Methodology 60
Coverage 60
Secondary Research 60
Primary Research 60
Expert Panel Validation 60
Contact Us 60
Disclaimer 61

List of Tables
Number of Products under Development for Dermatomycoses, H2 2016 8
Number of Products under Development for Dermatomycoses - Comparative Analysis, H2 2016 9
Number of Products under Development by Companies, H2 2016 10
Number of Products under Investigation by Universities/Institutes, H2 2016 11
Comparative Analysis by Late Stage Development, H2 2016 12
Comparative Analysis by Clinical Stage Development, H2 2016 13
Comparative Analysis by Early Stage Development, H2 2016 14
Comparative Analysis by Unknown Stage Development, H2 2016 15
Products under Development by Companies, H2 2016 16
Products under Investigation by Universities/Institutes, H2 2016 17
Dermatomycoses - Pipeline by Anacor Pharmaceuticals Inc, H2 2016 18
Dermatomycoses - Pipeline by Biolab Farmaceutica Ltda, H2 2016 19
Dermatomycoses - Pipeline by Blueberry Therapeutics Ltd, H2 2016 20
Dermatomycoses - Pipeline by Daewoong Pharmaceutical Co Ltd, H2 2016 21
Dermatomycoses - Pipeline by Dermala Inc, H2 2016 22
Dermatomycoses - Pipeline by Helix BioMedix Inc, H2 2016 23
Dermatomycoses - Pipeline by Novan Inc, H2 2016 24
Dermatomycoses - Pipeline by Sol-Gel Technologies Ltd, H2 2016 25
Dermatomycoses - Pipeline by TGV-Laboratories, H2 2016 26
Dermatomycoses - Pipeline by Viamet Pharmaceuticals Inc, H2 2016 27
Dermatomycoses - Pipeline by Vyome Biosciences Pvt Ltd, H2 2016 28
Assessment by Monotherapy Products, H2 2016 29
Number of Products by Stage and Target, H2 2016 31
Number of Products by Stage and Mechanism of Action, H2 2016 33
Number of Products by Stage and Route of Administration, H2 2016 35
Number of Products by Stage and Molecule Type, H2 2016 37
Dermatomycoses - Dormant Projects, H2 2016 56

List of Figures
Number of Products under Development for Dermatomycoses, H2 2016 8
Number of Products under Development for Dermatomycoses - Comparative Analysis, H2 2016 9
Number of Products under Development by Companies, H2 2016 10
Comparative Analysis by Clinical Stage Development, H2 2016 13
Comparative Analysis by Early Stage Products, H2 2016 14
Assessment by Monotherapy Products, H2 2016 29
Number of Products by Targets, H2 2016 30
Number of Products by Stage and Targets, H2 2016 30
Number of Products by Mechanism of Actions, H2 2016 32
Number of Products by Stage and Mechanism of Actions, H2 2016 32
Number of Products by Routes of Administration, H2 2016 34
Number of Products by Stage and Routes of Administration, H2 2016 34
Number of Products by Molecule Types, H2 2016 36
Number of Products by Stage and Molecule Types, H2 2016 36

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *